Biocardia Valuation
| BCDA Stock | USD 2.37 0.11 4.87% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Biocardia shows a prevailing Real Value of $3.03 per share. The current price of the firm is $2.37. Our model approximates the value of Biocardia from analyzing the firm fundamentals such as Shares Outstanding of 4.58 M, operating margin of (549.67) %, and Return On Equity of -7.04 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biocardia's valuation include:
Price Book 3.9465 | Enterprise Value 7 M | Enterprise Value Ebitda (3.16) | Price Sales 25.3849 | Enterprise Value Revenue 98.3064 |
Undervalued
Today
Please note that Biocardia's price fluctuation is extremely dangerous at this time. Calculation of the real value of Biocardia is based on 3 months time horizon. Increasing Biocardia's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biocardia is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biocardia Stock. However, Biocardia's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.37 | Real 3.03 | Target 4.0 | Hype 2.46 | Naive 2.29 |
The real value of Biocardia Stock, also known as its intrinsic value, is the underlying worth of Biocardia Company, which is reflected in its stock price. It is based on Biocardia's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biocardia's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biocardia helps investors to forecast how Biocardia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biocardia more accurately as focusing exclusively on Biocardia's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biocardia's intrinsic value based on its ongoing forecasts of Biocardia's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biocardia's closest peers. If more than one evaluation category is relevant for Biocardia we suggest using both methods to arrive at a better estimate.
Biocardia Cash |
|
Biocardia Valuation Trend
Comparing Biocardia's enterprise value against its market capitalization is a good way to estimate the value of Biocardia uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Biocardia Total Value Analysis
Biocardia is currently forecasted to have valuation of 6.98 M with market capitalization of 10.86 M, debt of 1.31 M, and cash on hands of 8.61 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biocardia fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.98 M | 10.86 M | 1.31 M | 8.61 M |
Biocardia Investor Information
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.03. Biocardia last dividend was issued on the 6th of June 2019. The entity had 1:15 split on the 30th of May 2024. Based on the key measurements obtained from Biocardia's financial statements, Biocardia may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Biocardia Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biocardia has an asset utilization ratio of 15.97 percent. This suggests that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Biocardia is more efficient with each dollar of assets it utilizes for everyday operations.Biocardia Ownership Allocation
The market capitalization of Biocardia is $10.86 Million. Biocardia shows 14.07 percent of its outstanding shares held by insiders and 2.21 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Biocardia Profitability Analysis
The company reported the previous year's revenue of 477 K. Net Loss for the year was (11.57 M) with loss before overhead, payroll, taxes, and interest of (7.48 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biocardia's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biocardia and how it compares across the competition.
About Biocardia Valuation
The stock valuation mechanism determines Biocardia's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biocardia. We calculate exposure to Biocardia's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biocardia's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -7.2 M | -6.9 M | |
| Pretax Profit Margin | (24.26) | (25.47) | |
| Operating Profit Margin | (24.41) | (25.63) | |
| Net Loss | (24.26) | (23.04) | |
| Gross Profit Margin | (15.20) | (14.44) |
Biocardia Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.4 M |
Biocardia Current Valuation Indicators
Valuation refers to the process of determining the present value of Biocardia and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Biocardia we look at many different elements of the entity such as Biocardia's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biocardia, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biocardia's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biocardia's worth.Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |